“ROLE OF INFLAMMATORY MARKERS CRP AND FERRITIN IN PANCREATIC DUCTAL ADENOCARCINOMA”
Main Article Content
Keywords
.................
Abstract
Being aggressively metastasizing to difficult to detect in early stages, pancreatic ductal adenocarcinoma has an extremely high mortality rate. With resistance to many anti cancer drugs to limitations on surgical resection, PDAC needs urgent measures to diagnose as well as monitor progression . Tumer size, metastasis staging, perinural spread are the prognostic factors determining the outcomes in PDAC.
Various molecular markers are potential predictors but have less practical use. These markers are expensive, required expert labs and take time. Hence is the need for cost effective , early and non-invasive biomarkers.
To formulate management plan, it is crucial to identify prognostic markers. Easily available and reliable markers may help in avoiding unnecessary investigations. No comprehensive study is done yet to consider inflammatory markers in diagnosis of PDAC . This study was aimed to evaluate the role of CRP, ferritin as baseline reliable markers in overall management of PDAC.
There is urgent requirement of reliable biomarker other than CA 19-9 to monitor detection and treatment of pancreatic cancer patients. Previous epidemiological reports have shown a large association of chronic pancreatitis, with higher risk of PDAC. On a molecular basis, inflammation promote oncogene activity and inhibit cancer cell aging.
References
1. oxidatively modified DNA bases. BioTechnologia 2011, 2, 159–165. [Google Scholar]
2. [ CrossRef ]
3. Wang, W.; Tabu, K.; Aimaitijiang, A.; Taga, T. Therapy-resistant nature of cancer stem cells
4. in view of iron metabolism. Inflamm. Regen. 2022, 42, 34.
2. Mai, T.T.; Hamaï, A.; Hienzsch, A.; Cañeque, T.; Müller, S.; Wicinski, J.; Cabaud, O.; Leroy,
5. C.; David, A.; Acevedo, V.; et al. Salinomycin kills cancer stem cells by sequestering iron in
6. lysosomes. Nat. Chem. 2017, 9, 1025–1033
3. Yanatori, I.; Nishina, S.; Kishi, F.; Hino, K. Newly uncovered biochemical and functional
7. aspects of ferritin. FASEB J. 2023, 37, e23095.
4. Shesh, B.P.; Connor, J.R. A novel view of ferritin in cancer. Biochim. Biophys. Acta Rev.
8. Cancer 2023, 1878, 188917.
5. Global Burden of Disease Cancer C , Fitzmaurice C, Abate D, Abbasi N, et al.
9. Global, regional, and national cancer incidence, mortality, years of life lost,
10. years lived with disability, and disability‐adjusted life‐years for 29 cancer
11. groups, 1990 to 2017: a systematic analysis for the global burden of disease
12. study. JAMA Oncol. 2019;5:1749‐1768. - PMC - PubMed
6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin.
13. 2020;70(1):7‐30. - PubMed
7. McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS.
14. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and
15. outcomes. World J Gastroenterol. 2018;24(43):4846‐4861
8. Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis
16. MV. Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment
17. and immunotherapy. World J Gastrointest Oncol. 2020; 12(2): 173-181.
9. Yanatri, I,; Nishina, S.; Kishi,F.; Newly uncovered biochemical and functional aspects pf ferritin. FASEBJ. 2023,37,e23095.
10. Shesh, B.P.; Connor, J.R. A novel view of ferritin in cancer. Biochem.
18. Biophys. Acta Rev. Cancer 2023, 1878, 188917.
11. Szkanda J, Stotz M, Absenger G, Kornprat P et al. validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer. 2014;110:183-188. PMID : 24201751.
19. 13.Douglas JB, Silverman DT, Weinstein SJ, Graubard BI, Pollak MN, Tao Y, et al. Serum C-reactive protein and risk of pancreatic cancer in two nested, case–control studies. Cancer Epidemiol Biomarkers Prev. 2011;20(2):359–69.
20. 14.Kalousova M, Krechler T, Jachymova M, Kubena AA, Zak A, Zima T. Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumour Biol. 2012;33(5):1695–700.
21. 15.Basso D, Fabris C, Del Favero G, Meggiato T, Panozzo MP, Vianello D, et al. Hepatic changes and serum ferritin in pancreatic cancer and other gastrointestinal diseases: the role of cholestasis. Ann Clin Biochem. 1991;28(Pt 1):34–8.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Farheen B. Mujawar
(P.hD Student) Tutor, Department of Biochemistry, SKNMC& GH, Pune.
Dr.Vanita jagtap
(P.hD guide), Associate Professor, Department of Biochemistry, Government Medical College, Miraj.
Dr. Sardeshmukh A. S.
Professor and Head, Department of Biochemistry, Government Medical College, Miraj.
Shubhangidevi H. Gawade.
Tutor, Department of Biochemistry, SKNMC& GH, Pune.
Dr. G.A.Gulavani,
Professor and Head, Dept. of Biochemistry, SKNMCGH, Pune
